In vitro activity of tigecycline, a new glycylcycline, tested against 1,326 clinical bacterial strains isolated from Latin America
Autor(a) principal: | |
---|---|
Data de Publicação: | 2005 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Brazilian Journal of Infectious Diseases |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702005000500001 |
Resumo: | The in vitro activity of tigecycline (former GAR-936), a new semisynthetic tetracycline, was evaluated in comparison with tetracycline and other antimicrobial agents. MATERIAL AND METHODS: A total of 1,326 contemporary clinical isolates collected from the Latin American region were collected in 2000-2002 period and tested with microdilution broth according to the CLSI guidelines. The bacterial pathogens evaluated included Staphylococcus aureus (505), Streptococcus pneumoniae (269), coagulase-negative staphylococci (CoNS; 227), Haemophilus influenzae (129), Enterococcus spp. (80), Moraxella catarrhalis (54), beta-haemolytic streptococci (28), viridans group streptococci (26), and Neisseria meningitidis (8) RESULTS:Tigecycline demonstrated excellent activity against all Gram-positive cocci, with 90% of penicillin-resistant S. pneumoniae strains being inhibited at 0.12 µg/mL, while the same isolates had an MIC90 of > 16 µg/mL for tetracycline. All Enterococcus spp. were inhibited at 0.25 µg/mL of tigecycline. Tigecycline (MIC50, 0.25 µg/mL) was eight-fold more potent than minocycline (MIC50, 2 µg/mL) against oxacillin-resistant S. aureus (ORSA); all ORSA were inhibited at < 2 µg/mL of tigecycline. Tigecycline demonstrated excellent activity (MIC50, 0.5 µg/mL) against CoNS with reduced susceptibility to teicoplanin (MIC, 16 µg/mL). Tigecycline also showed high potency against respiratory pathogens such as M. catarrhalis (MIC50, 0.12 µg/mL) and H. influenzae (MIC50, 0.5 µg/mL). No tigecycline resistant isolates were detected when the proposed susceptible breakpoints (< 4 µg/mL) was applied. CONCLUSIONS: This results indicate that tigecycline has potent in vitro activity against clinically important pathogenic bacteria, including Gram-positive isolates resistant to both tetracycline and minocycline. |
id |
BSID-1_46a5c30ab6918295af48b7fdfecf7a93 |
---|---|
oai_identifier_str |
oai:scielo:S1413-86702005000500001 |
network_acronym_str |
BSID-1 |
network_name_str |
Brazilian Journal of Infectious Diseases |
repository_id_str |
|
spelling |
In vitro activity of tigecycline, a new glycylcycline, tested against 1,326 clinical bacterial strains isolated from Latin AmericaAntimicrobial susceptibilitytigecyclineLatin America and SENTRYThe in vitro activity of tigecycline (former GAR-936), a new semisynthetic tetracycline, was evaluated in comparison with tetracycline and other antimicrobial agents. MATERIAL AND METHODS: A total of 1,326 contemporary clinical isolates collected from the Latin American region were collected in 2000-2002 period and tested with microdilution broth according to the CLSI guidelines. The bacterial pathogens evaluated included Staphylococcus aureus (505), Streptococcus pneumoniae (269), coagulase-negative staphylococci (CoNS; 227), Haemophilus influenzae (129), Enterococcus spp. (80), Moraxella catarrhalis (54), beta-haemolytic streptococci (28), viridans group streptococci (26), and Neisseria meningitidis (8) RESULTS:Tigecycline demonstrated excellent activity against all Gram-positive cocci, with 90% of penicillin-resistant S. pneumoniae strains being inhibited at 0.12 µg/mL, while the same isolates had an MIC90 of > 16 µg/mL for tetracycline. All Enterococcus spp. were inhibited at 0.25 µg/mL of tigecycline. Tigecycline (MIC50, 0.25 µg/mL) was eight-fold more potent than minocycline (MIC50, 2 µg/mL) against oxacillin-resistant S. aureus (ORSA); all ORSA were inhibited at < 2 µg/mL of tigecycline. Tigecycline demonstrated excellent activity (MIC50, 0.5 µg/mL) against CoNS with reduced susceptibility to teicoplanin (MIC, 16 µg/mL). Tigecycline also showed high potency against respiratory pathogens such as M. catarrhalis (MIC50, 0.12 µg/mL) and H. influenzae (MIC50, 0.5 µg/mL). No tigecycline resistant isolates were detected when the proposed susceptible breakpoints (< 4 µg/mL) was applied. CONCLUSIONS: This results indicate that tigecycline has potent in vitro activity against clinically important pathogenic bacteria, including Gram-positive isolates resistant to both tetracycline and minocycline.Brazilian Society of Infectious Diseases2005-10-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702005000500001Brazilian Journal of Infectious Diseases v.9 n.5 2005reponame:Brazilian Journal of Infectious Diseasesinstname:Brazilian Society of Infectious Diseases (BSID)instacron:BSID10.1590/S1413-86702005000500001info:eu-repo/semantics/openAccessGales,Ana C.Jones,Ronald N.Andrade,Soraya S.Pereira,Andrea S.Sader,Hélio S.eng2006-01-06T00:00:00Zoai:scielo:S1413-86702005000500001Revistahttps://www.bjid.org.br/https://old.scielo.br/oai/scielo-oai.phpbjid@bjid.org.br||lgoldani@ufrgs.br1678-43911413-8670opendoar:2006-01-06T00:00Brazilian Journal of Infectious Diseases - Brazilian Society of Infectious Diseases (BSID)false |
dc.title.none.fl_str_mv |
In vitro activity of tigecycline, a new glycylcycline, tested against 1,326 clinical bacterial strains isolated from Latin America |
title |
In vitro activity of tigecycline, a new glycylcycline, tested against 1,326 clinical bacterial strains isolated from Latin America |
spellingShingle |
In vitro activity of tigecycline, a new glycylcycline, tested against 1,326 clinical bacterial strains isolated from Latin America Gales,Ana C. Antimicrobial susceptibility tigecycline Latin America and SENTRY |
title_short |
In vitro activity of tigecycline, a new glycylcycline, tested against 1,326 clinical bacterial strains isolated from Latin America |
title_full |
In vitro activity of tigecycline, a new glycylcycline, tested against 1,326 clinical bacterial strains isolated from Latin America |
title_fullStr |
In vitro activity of tigecycline, a new glycylcycline, tested against 1,326 clinical bacterial strains isolated from Latin America |
title_full_unstemmed |
In vitro activity of tigecycline, a new glycylcycline, tested against 1,326 clinical bacterial strains isolated from Latin America |
title_sort |
In vitro activity of tigecycline, a new glycylcycline, tested against 1,326 clinical bacterial strains isolated from Latin America |
author |
Gales,Ana C. |
author_facet |
Gales,Ana C. Jones,Ronald N. Andrade,Soraya S. Pereira,Andrea S. Sader,Hélio S. |
author_role |
author |
author2 |
Jones,Ronald N. Andrade,Soraya S. Pereira,Andrea S. Sader,Hélio S. |
author2_role |
author author author author |
dc.contributor.author.fl_str_mv |
Gales,Ana C. Jones,Ronald N. Andrade,Soraya S. Pereira,Andrea S. Sader,Hélio S. |
dc.subject.por.fl_str_mv |
Antimicrobial susceptibility tigecycline Latin America and SENTRY |
topic |
Antimicrobial susceptibility tigecycline Latin America and SENTRY |
description |
The in vitro activity of tigecycline (former GAR-936), a new semisynthetic tetracycline, was evaluated in comparison with tetracycline and other antimicrobial agents. MATERIAL AND METHODS: A total of 1,326 contemporary clinical isolates collected from the Latin American region were collected in 2000-2002 period and tested with microdilution broth according to the CLSI guidelines. The bacterial pathogens evaluated included Staphylococcus aureus (505), Streptococcus pneumoniae (269), coagulase-negative staphylococci (CoNS; 227), Haemophilus influenzae (129), Enterococcus spp. (80), Moraxella catarrhalis (54), beta-haemolytic streptococci (28), viridans group streptococci (26), and Neisseria meningitidis (8) RESULTS:Tigecycline demonstrated excellent activity against all Gram-positive cocci, with 90% of penicillin-resistant S. pneumoniae strains being inhibited at 0.12 µg/mL, while the same isolates had an MIC90 of > 16 µg/mL for tetracycline. All Enterococcus spp. were inhibited at 0.25 µg/mL of tigecycline. Tigecycline (MIC50, 0.25 µg/mL) was eight-fold more potent than minocycline (MIC50, 2 µg/mL) against oxacillin-resistant S. aureus (ORSA); all ORSA were inhibited at < 2 µg/mL of tigecycline. Tigecycline demonstrated excellent activity (MIC50, 0.5 µg/mL) against CoNS with reduced susceptibility to teicoplanin (MIC, 16 µg/mL). Tigecycline also showed high potency against respiratory pathogens such as M. catarrhalis (MIC50, 0.12 µg/mL) and H. influenzae (MIC50, 0.5 µg/mL). No tigecycline resistant isolates were detected when the proposed susceptible breakpoints (< 4 µg/mL) was applied. CONCLUSIONS: This results indicate that tigecycline has potent in vitro activity against clinically important pathogenic bacteria, including Gram-positive isolates resistant to both tetracycline and minocycline. |
publishDate |
2005 |
dc.date.none.fl_str_mv |
2005-10-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702005000500001 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702005000500001 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/S1413-86702005000500001 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Brazilian Society of Infectious Diseases |
publisher.none.fl_str_mv |
Brazilian Society of Infectious Diseases |
dc.source.none.fl_str_mv |
Brazilian Journal of Infectious Diseases v.9 n.5 2005 reponame:Brazilian Journal of Infectious Diseases instname:Brazilian Society of Infectious Diseases (BSID) instacron:BSID |
instname_str |
Brazilian Society of Infectious Diseases (BSID) |
instacron_str |
BSID |
institution |
BSID |
reponame_str |
Brazilian Journal of Infectious Diseases |
collection |
Brazilian Journal of Infectious Diseases |
repository.name.fl_str_mv |
Brazilian Journal of Infectious Diseases - Brazilian Society of Infectious Diseases (BSID) |
repository.mail.fl_str_mv |
bjid@bjid.org.br||lgoldani@ufrgs.br |
_version_ |
1754209239067262976 |